Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies

Author(s): Rafael Bonamichi-Santos and Mariana Castells

Volume 22, Issue 45, 2016

Page: [6870 - 6880] Pages: 11

DOI: 10.2174/1381612822666161025154506

Price: $65

Abstract

Chemotherapies drugs and monoclonal antibodies are key components of the treatment of cancer patients and patients with chronic inflammatory conditions to provide increase in life expectancy and quality of life. Their increased use has lead to an increase in drugs hypersensitivity reactions (DHR) worldwide. DHR to those agents prevented their use and promoted the use of second line therapies to protect patients’ hypersensitive reactions and anaphylaxis. Second line medications may not fully address the patients’ medical condition and it is desirable to keep patients on first line therapy.

Drug hypersensitivity symptoms can range from mild cutaneous reactions to life-threatening anaphylaxis.

Rapid drug desensitization (RDD) is a novel approach to the management of drug hypersensitivity reactions which are IgE and non-IgE mediated. Through the diferent desensitization protocols patients can receive the full dose of the medications that they have presented a hypersensitive reaction and been protected against anaphylaxis.

This review looks at the current literature on hypersensitivity reactions (HSR) to chemotherapy drugs and monoclonal antibodies and the potential use of RDD for their management.

Keywords: Chemotherapy, Monoclonal antibodies, Rapid drug desensitization, Drug hypersensitivity reaction, Adverse drug reaction.

« Previous

Rights & Permissions Print Cite
Article Metrics
97
13
3
3
© 2024 Bentham Science Publishers | Privacy Policy